Immune escape mechanism of B-cell malignancies on Anti-CD19 Chimeric Antigen Receptor T-cell treatment and solution

Relapse or refractory B-cell malignancies have been reported in multiple clinical trials after treatment of Anti-CD19 Chimeric Antigen Receptor (CAR) T-cells. Many studies demonstrated the potential immune escape mechanism for like genetic mutation, transcriptional deregulation, lineage switch, loss CAR T-cells, and trogocytosis. The study these mechanisms can provide us insights designs future immunotherapies regarding both even other solid tumors. solution T-cell is engineering multispecific CARs. In this article, I review most upto- date some that may prevent route to cure malignancies.